The Swedish National Care Programme for Anal Carcinoma: Implementation and Overall Results

Authors

  • Bertil Friberg From the Department of Surgery, Karolinska Institute, So dersjukhuset (B. Friberg), Southern Stockholm’s Department of Oncology, Huddinge University Hospital (C. Svensson), Department of Surgery, Ersta Hospital (S. Goldman), Stockholm, Sweden, and the Department of Oncology, University of Uppsala, Akademiska sjukhuset (B. Glimelius), Uppsala, Sweden
  • Christer Svensson From the Department of Surgery, Karolinska Institute, So dersjukhuset (B. Friberg), Southern Stockholm’s Department of Oncology, Huddinge University Hospital (C. Svensson), Department of Surgery, Ersta Hospital (S. Goldman), Stockholm, Sweden, and the Department of Oncology, University of Uppsala, Akademiska sjukhuset (B. Glimelius), Uppsala, Sweden
  • Sven Goldman From the Department of Surgery, Karolinska Institute, So dersjukhuset (B. Friberg), Southern Stockholm’s Department of Oncology, Huddinge University Hospital (C. Svensson), Department of Surgery, Ersta Hospital (S. Goldman), Stockholm, Sweden, and the Department of Oncology, University of Uppsala, Akademiska sjukhuset (B. Glimelius), Uppsala, Sweden
  • Bengt Glimelius From the Department of Surgery, Karolinska Institute, So dersjukhuset (B. Friberg), Southern Stockholm’s Department of Oncology, Huddinge University Hospital (C. Svensson), Department of Surgery, Ersta Hospital (S. Goldman), Stockholm, Sweden, and the Department of Oncology, University of Uppsala, Akademiska sjukhuset (B. Glimelius), Uppsala, Sweden

DOI:

https://doi.org/10.1080/028418698423140

Abstract

The Swedish National Care Programme for Anal Carcinoma (SNCPAC) was instituted in order to create a uniform handling policy for anal cancer and thus to accrue a population-based material allowing unbiased analyses. This study evaluates the degree of implementation of the SNCPAC guidelines, and presents overall treatment results in a total of 356 patients with epidermoid cancer of the anus and the perianal region diagnosed in Sweden between 1985 and 1989. Primary treatment according to the guidelines was irradiation up to 40 Gy. Bleomycin was administered intramuscularly before the first 18 fractions. After a 3-week pause, radiotherapy was to be continued up to a dose of 60-64 Gy, if at least an almost complete response was achieved. Otherwise, the patient was recommended surgery within a week. The guidelines were applied in 90% of cases where such treatment was possible. The 5-year tumour-specific survival rate was 72%. The survival rate was more favourable in perianal tumours (90%) than in anal canal tumours (68%, p<0.01). The 5-year probability of having a preserved anus was 64% (anal canal/perianal 58%/91%, p<0.001). Bleomycin did not appear to have any effect on treatment results. The care programme has had a rapid and almost complete nation-wide penetration, and h as created the desired uniformity allowing proper analyses. The treatment results also appear comparable with specialised referral centres.

Downloads

Download data is not yet available.

Downloads

Published

1998-01-01

How to Cite

Friberg, B. ., Svensson, C. ., Goldman, S. ., & Glimelius, B. . (1998). The Swedish National Care Programme for Anal Carcinoma: Implementation and Overall Results. Acta Oncologica, 37(1), 25–32. https://doi.org/10.1080/028418698423140